GlassScriptPhysician profile
Aaron M Bartek
NPI 1194292813
$10,905.24
in general payments reported to CMS, 2019-2025
35 companies · $3,826 in 2025
The $3,826 reported for 2025 was more than what 98% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,317 · 2022: $1,258 · 2023: $2,530 · 2024: $1,973 · 2025: $3,826.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,416 · Consulting Fee: $1,785 · Education: $129.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,416.18 |
| Consulting Fee | $1,785.00 |
| Education | $128.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tg Therapeutics, INC. | $2,313.19 | 2023-2025 | |
| Biogen, INC. | $1,718.39 | 2021-2025 | Tysabri, Vumerity, Avonex |
| Novartis Pharmaceuticals Corporation | $1,372.68 | 2021-2025 | Kesimpta |
| Abbvie INC. | $838.96 | 2021-2025 | |
| Emd Serono, INC. | $816.15 | 2022-2025 | Mavenclad |
| Celgene Corporation | $758.27 | 2021-2025 | Zeposia |
| Genzyme Corporation | $606.85 | 2021-2025 | |
| Lilly USA, LLC | $340.32 | 2022-2025 | Emgality, Kisunla |
| Genentech USA, INC. | $286.74 | 2021-2025 | Ocrevus, Ocrevus Zunovo |
| Janssen Pharmaceuticals, INC | $200.81 | 2021-2023 | Ponvory |
| Mallinckrodt Hospital Products INC. | $181.83 | 2021-2025 | Acthar |
| Ani Pharmaceuticals, INC. | $169.26 | 2022-2025 | Purified Cortrophin Gel |
| Vanda Pharmaceuticals INC. | $165.02 | 2024-2025 | Ponvory |
| Ipsen Biopharmaceuticals, INC | $135.89 | 2023-2025 | Dysport |
| Otsuka America Pharmaceutical, INC. | $126.62 | 2023-2025 | Nuedexta |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Piramal Critical Care | $120.14 | 2025 | |
| Biohaven Pharmaceutical Holding Company LTD. | $88.99 | 2022 | |
| Banner Life Sciences, LLC | $88.63 | 2023-2024 | |
| Lundbeck LLC | $71.78 | 2022-2024 | Vyepti |
| Acorda Therapeutics, INC | $60.75 | 2021-2024 | Ampyra |
| Allergan, INC. | $55.02 | 2021-2022 | |
| Pfizer INC. | $54.06 | 2023-2025 | |
| Medtronic, INC. | $50.18 | 2021-2025 | Synchromedii |
| Avanir Pharmaceuticals, INC. | $42.82 | 2021-2022 | |
| Arbor Pharmaceuticals, INC. | $39.82 | 2021-2022 | |
| Cycle Pharmaceuticals INC | $35.43 | 2025 | Bafiertam |
| Sumitomo Pharma America, INC. | $32.02 | 2023 | Gemtesa |
| Azurity Pharmaceuticals, INC. | $20.38 | 2024 | Horizant |
| Horizon Therapeutics Plc | $18.68 | 2022 | |
| Axsome Therapeutics, INC. | $18.36 | 2023 | Sunosi |
| Merz Pharmaceuticals, LLC | $17.12 | 2025 | Xeomin, Ampyra |
| 180 Medical, INC. | $16.15 | 2022 | |
| Esperion Therapeutics, INC. | $15.55 | 2021 | |
| Sandoz INC. | $15.10 | 2025 | Tyruko |
| Pacira Pharmaceuticals Incorporated | $13.28 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Aaron Bartek listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.